• Fresenius maintained its full-year 2026 outlook.
• Biopharma revenue is targeted to nearly double by 2030 from 2025, with an EBIT margin of around 20%.
• The company expects to significantly raise its longer-term Biopharma ambitions following an exclusive development agreement with WuXi Biologics.
• The agreement provides access to up to 37 biosimilar candidates, potentially expanding the portfolio from 29 to 66 molecules over a decade.
• Rising development spending will weigh on profitability before products contribute growth; operating cash flow will fund the agreement without additional debt.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fresenius SE & Co. KGaA published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2426078_de) on November 02, 2026, and is solely responsible for the information contained therein.